These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12476969)

  • 1. ABC transporters and inhibitors: new targets, new agents.
    Leonard GD; Polgar O; Bates SE
    Curr Opin Investig Drugs; 2002 Nov; 3(11):1652-9. PubMed ID: 12476969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
    Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
    Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversing agents for ATP-binding cassette drug transporters.
    Lee CH
    Methods Mol Biol; 2010; 596():325-40. PubMed ID: 19949930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
    Modok S; Mellor HR; Callaghan R
    Curr Opin Pharmacol; 2006 Aug; 6(4):350-4. PubMed ID: 16690355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
    Erić S; Kalinić M; Ilić K; Zloh M
    SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review.
    Sosnik A
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1828-51. PubMed ID: 24055628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.
    Thomas H; Coley HM
    Cancer Control; 2003; 10(2):159-65. PubMed ID: 12712010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressors as multidrug resistance reversal agents.
    Morjani H; Madoulet C
    Methods Mol Biol; 2010; 596():433-46. PubMed ID: 19949935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?
    Steinbach D; Legrand O
    Leukemia; 2007 Jun; 21(6):1172-6. PubMed ID: 17429427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells.
    Li S; Lei Y; Jia Y; Li N; Wink M; Ma Y
    Phytomedicine; 2011 Dec; 19(1):83-7. PubMed ID: 21802927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.
    Chen Z; Shi T; Zhang L; Zhu P; Deng M; Huang C; Hu T; Jiang L; Li J
    Cancer Lett; 2016 Jan; 370(1):153-64. PubMed ID: 26499806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier.
    Robillard KR; Hoque T; Bendayan R
    J Pharmacol Exp Ther; 2012 Jan; 340(1):96-108. PubMed ID: 21990609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibition of ABC-transporter(s)' function in non-small cell lung cancer cells by platinum drugs].
    Bogush TA; Konukhova AV; Ravcheeva AB; Zabotina TN; Kadagidze ZG; Bogush EA; Komov DV; Polotskiĭ BE; Laktionov KK; Davydov MI
    Antibiot Khimioter; 2003; 48(10):11-5. PubMed ID: 15004974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of multidrug resistance in the age of targeted therapy.
    Türk D; Szakács G
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
    Weiss J; Haefeli WE
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microparticles and their emerging role in cancer multidrug resistance.
    Gong J; Jaiswal R; Mathys JM; Combes V; Grau GE; Bebawy M
    Cancer Treat Rev; 2012 May; 38(3):226-34. PubMed ID: 21757296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
    Binkhathlan Z; Lavasanifar A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy.
    Lazarowski A; Czornyj L; Lubienieki F; Girardi E; Vazquez S; D'Giano C
    Epilepsia; 2007; 48 Suppl 5():140-9. PubMed ID: 17910594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.